However, knowing that stanniocalcin‐2 inhibits the enzymatic function of PAPP‐A, one may argue that by obstructing PAPP‐A, stanniocalcin‐2 was indeed delaying the recurrence of breast cancer rather than serving as a survival factor. Here, PAPPA is linked to breast carcinoma.